JLKE, Participates in ‘Stroke 2025 JAPAN’... “Full-Scale Entry into the Japanese Market”

Stroke AI specialist JLK (CEO Dongmin Kim) announced that it will participate in the Japan Stroke Society Conference (Stroke 2025) and the Korea-Japan Joint Stroke Conference (KJJSC 2025), held for three days from the 6th at the Osaka International Convention Center in Japan, marking the official entry into the Japanese medical AI market.

Stroke 2025 is the largest stroke academic event in Japan hosted by the Japan Stroke Society, providing a platform to share the latest stroke diagnosis and treatment technologies and research achievements.

Through this event, JLK plans to focus on introducing its PMDA (Pharmaceuticals and Medical Devices Agency) approved ▲JLK-CTP ▲JLK-PWI ▲NCCT AI solutions. The NCCT (Non-Contrast CT) AI solution is a product of high interest to Japanese medical professionals, as it supports rapid diagnosis of cerebral hemorrhage and cerebral infarction without using contrast agents, expected to be highly useful in emergency situations.

In addition, JLK will exhibit FDA-approved solutions (U.S. approval names: JBS-LVO, JLK-ICH, JLK-Ailink, JLK-SDH) and domestic non-reimbursed solutions (JBS-01K) to actively promote its technological capabilities to Japanese medical staff and stakeholders.

The company plans to accelerate its entry into the Japanese medical market and strengthen marketing activities starting with participation in Stroke 2025. Along with ongoing PMDA approval applications, JLK aims to rapidly expand its supply network within Japan by finalizing dealership contracts with well-known Japanese trading companies and medical device subsidiaries.

The industry also holds a positive outlook on JLK’s expansion into the Japanese market. Demand for AI-based stroke solutions is increasing in the Japanese medical market, and the Japanese government is implementing policies that recognize additional fees when AI solutions are used in hospitals above a certain scale.

Notably, the Korea-Japan Joint Stroke Conference will host a clinical seminar featuring participants such as ▲JLK, Inc ▲Bayer Yakuhin, Ltd ▲AstraZeneca K.K, Medical Affairs.

JLK will host the evening seminar on the second day (March 7th) with speakers including Professor Dong-eok Kim (Dongguk University Ilsan Hospital), Professor Beom-jun Kim (Seoul National University Bundang Hospital), and Professor Manabu Inoue (Manabu Inoue, National Cerebral and Cardiovascular Center, Japan). This seminar will highlight the usage experience and excellence of JLK AI solutions as directly experienced by renowned stroke experts from Korea and Japan.

JLK CEO Dongmin Kim stated, “Participation in Stroke 2025 will be a significant turning point for JLK to fully penetrate the Japanese market,” adding, “Based on AI solutions approved by PMDA, we will expand our presence in the Japanese medical market and strengthen cooperation with local medical device distributors to rapidly increase sales in Japan.”

He further noted, “Japan, as a representative aging country, faces a growing number of stroke patients each year, making it a major social issue,” and added, “Leading Japanese hospitals are actively considering the introduction of AI-based solutions to improve the efficiency of acute stroke treatment, which raises great expectations.”